

15 May 2019

Oncimmune Holdings plc
(“Oncimmune” or the “Company”)

Regulatory Approval in Israel for *EarlyCDT*®—Lung

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, today announces that its distributor for Israel, Best Medical Opinion, has received regulatory approval for the sale of *EarlyCDT*—Lung in Israel.

On an age standardised basis, Israel’s lung cancer mortality rate is 18.2 per 100,000 persons, making it one of the highest rates in the Middle East region. Lung cancer is responsible for more cancer-related deaths than any other cancer in Israel.¹

Dr Adam M Hill, CEO of Oncimmune commented: *“We welcome this latest approval which paves the way for the near-term commencement of commercial sales in the sophisticated healthcare market of Israel.”*

-Ends-

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones, Mike Seabrook

+44 (0)20 3829 5000

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

Oncimmune@consilium-comms.com

+44 (0)20 3709 5700

About Oncimmune

Beating cancer, one test at a time

Oncimmune is a leader in the development, manufacture and commercialisation of cancer specific immunodiagnostics for the screening, detection and care of cancer. Oncimmune also develops precision medicine and patient stratification tools for leading pharmaceutical

¹ International Agency for Research on Cancer, World Health Organization - 2018

multinationals in both immuno-oncology and autoimmune disease. Oncimmune is working to change how cancer is diagnosed and treated. Its patented technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis. Oncimmune's tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. Oncimmune partners with leading developers and distributors to make our technology available globally.

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, **EarlyCDT—Lung** and **EarlyCDT—Liver**. To date, over 155,000 tests have been performed for patients worldwide and **EarlyCDT—Lung** is being used in the largest-ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) ECLS study of 12,210 high-risk smokers in Scotland. Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as offices in London, UK and Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker **ONC.L**.

What is *EarlyCDT—Lung*?

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

For more information, visit www.oncimmune.com